What is Ethris?
Ethris is at the forefront of therapeutic protein discovery and development, leveraging a proprietary, non-immunogenic mRNA technology platform. With over a decade of pioneering work in mRNA, the company has established itself as a global leader in delivering stabilized mRNAs directly to the respiratory system. This is achieved through optimized formulation and advanced nebulization technologies. Ethris is actively progressing its pipeline, focusing on immuno-modulation and mRNA-based protein replacement therapies, with the overarching aim of significantly improving patient outcomes.
How much funding has Ethris raised?
Ethris has raised a total of $59.3M across 3 funding rounds:
Series A
$28M
Series B
$26.3M
Other Financing Round
$5M
Series A (2017): $28M with participation from Orbimed and HS Life Sciences
Series B (2022): $26.3M led by Laureus Capital
Other Financing Round (2024): $5M supported by Bill & Melinda Gates Foundation
Key Investors in Ethris
Orbimed
Orbimed is a global investment firm focused on the healthcare sector, likely bringing strategic insights and capital to Ethris's therapeutic development.
Laureus Capital
Laureus Capital, a group of serial entrepreneurs focused on tech and digital innovation, provides strategic investment and operational expertise to companies like Ethris.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation supports global health initiatives and likely sees Ethris's mRNA technology as a key enabler for addressing significant health challenges.
What's next for Ethris?
The recent major strategic investment signifies a critical juncture for Ethris, likely enabling the company to scale its operations, expand its research and development efforts, and potentially accelerate clinical trials for its innovative therapies. This infusion of capital, coupled with the company's established expertise in mRNA delivery, suggests a strategic focus on commercialization and market penetration. Ethris is well-positioned to capitalize on the growing demand for advanced biotherapeutics, particularly in the respiratory and immuno-modulation fields.
See full Ethris company page
